AbbVie marked a 0.8% change today, compared to 1.0% for the S&P 500. Is it a good value at today's price of $147.54? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:
-
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
-
AbbVie belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 30.21 and an average price to book (P/B) of 4.08
-
The company's P/B ratio is 21.54
-
AbbVie has a trailing 12 month Price to Earnings (P/E) ratio of 40.5 based on its trailing 12 month price to earnings (EPS) of $3.64 per share
-
Its forward P/E ratio is 13.2, based on its forward earnings per share (EPS) of $11.14
-
ABBV has a Price to Earnings Growth (PEG) ratio of -3.12, which shows the company has a fair value when we factor growth into the price to earnings calculus.
-
Over the last four years, AbbVie has averaged free cash flows of $18.89 Billion, which on average grew 11.6%
-
ABBV's gross profit margins have averaged 28.8 % over the last four years and during this time they had a growth rate of 6.2 % and a coefficient of variability of 190.0 %.
-
AbbVie has moved -10.0% over the last year compared to 17.0% for the S&P 500 -- a difference of -27.0%
-
ABBV has an average analyst rating of buy and is -13.15% away from its mean target price of $169.88 per share